According to the dysregulation of host immune responses in the development of cytokine release syndrome (CRS) as pathologic keystone for disease evolution of Covid‐19, inhibition of IL‐6 may be a novel target for therapeutics in patients with Covid‐19. Here, IL6 is linked to COVID-19.